ROME, AUG 19 - An Italo-US team of scientists have made a breakthrough in the early diagnosis of amyotrophic lateral sclerosis (ALS), also known as Motor Neuron Disease or Lou Gehrig's Disease, ...

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

Robin Leaper lost her voice to ALS. Artificial Intelligence has given her back the ability to speak with her own voice.

Stanford University scientists have developed a brain implant designed to "hear" and vocalize words a person with severe ...

"MTPA’s Radicava shows long-term benefit in ALS trials" was originally created and published by Clinical Trials Arena, a ...

Amyotrophic lateral sclerosis, known as ALS, is a neurodegenerative disorder which affects motor neurons. These are the neuronal cells responsible for muscle innervation, whose degenerations leads ...

The long-term data supports the drug’s progression into the HEALEY ALS Platform trial, with NUZ-001 dosing set to commence in Q4 2025. This will only begin, however, if the US Food and Drug ...

Summary: A new study has uncovered why some motor neurons resist degeneration in ALS while others succumb. Researchers found ...

Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.